Navigation Links
PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial
Date:4/13/2011

ANNAPOLIS, Md., April 13, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that it has completed dosing in a U.S. Phase I clinical trial of its fully human anti-toxin monoclonal antibody, Valortim®, being developed for the prevention and treatment of inhalational anthrax.

The randomized, placebo-controlled, double-blind Phase I clinical trial was designed to evaluate single escalating doses of 1, 5, or 10 mg/kg of Valortim® (or placebo) administered intravenously over a 120 minute infusion period.  A total of 28 participants, all healthy male and female volunteers between the ages of 18 and 60 years, were enrolled in the study.

"We have completed dosing of all 28 subjects and are pleased to report that no infusion-related adverse reactions have been observed in the current Phase I trial.  We anticipate that safety follow-up will be completed in the third quarter of 2011 with final unblinded results available later in the year," remarked Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer.

"This represents an important step in the development of Valortim®, which is being developed to meet the criteria for stockpiling in the U.S. Strategic National Stockpile," continued Dr. Fuerst.  "In preclinical animal studies Valortim® has been shown to protect both rabbits and monkeys against the lethal effects of anthrax infection when administered at the time of exposure, at doses as low as 1.0 mg/kg.  When administered to rabbits after the development of symptoms, Valortim® also improved survival as late as 48 hours post-exposure as compared to control animals.  We look forward to completing the Phase I clinical trial, which will provide important information about the IV dosing schedule for Valortim® in humans."  

The Valortim® project has been conducted with
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
4. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
5. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
6. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
7. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
8. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
9. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
10. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
11. PharmAthene Presents New Data for Lyophilized rPA Anthrax Vaccine Showing Enhanced Immunogenicity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 2014 The Cadence Fitness & Health Center has ... Medical Fitness Association, a non-profit organization assisting medically integrated ... The Cadence Fitness & Health Center is the only ... in the Chicagoland area. "The certification means ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Boston Scientific Corporation (NYSE: BSX ) ... quality of life outcomes, based on one-year data from ... while the overall cost effectiveness of percutaneous coronary intervention ... according to patient characteristics, PCI was more cost effective ...
... to be presented at Israel Society of ... reach 5 months from single treatment - Data ... scores of expensive injections MISGAV, Israel and LONDON, March ... that the latest, encouraging results of the Company,s ongoing ...
Cached Medicine Technology:SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 5Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 2Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 3Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 4
(Date:4/17/2014)... as the leading weapon against the deadly disease could ... research indicating it simply needs to be administered differently. ... cheap anti-malarial drug chloroquine in treating and preventing the ... half a million people each year around the world. ... to chloroquine, but research carried out at the Australian ...
(Date:4/16/2014)... 15, 2014 The Translational Genomics Research Institute (TGen) ... Founders Dinner for their support of TGen,s research into ... March 28 in Scottsdale. , Catherine Ivy, Founder and ... TGen,s John S. McCain Leadership Award, named for U.S. ...
(Date:4/16/2014)... , DOWNERS GROVE, Ill. April 16, 2014 ... of surveillance colonoscopy in average-risk patients with one to ... about 90 percent of cases. This may be an ... multicenter endoscopic database study to quantify adherence to guidelines ...
(Date:4/15/2014)... fish caused nearly half of all injuries aboard commercial ... freezer-longliner vessels operating off the coast of Alaska, new ... those injuries and others aboard the two types of ... the research methods used in the study could help ...
(Date:4/15/2014)... the University of California, San Diego School of Medicine have ... C virus get liver disease and why the virus is ... , The hard-to-kill pathogen, which infects an estimated 200 million ... mitochondria dismantling the cell,s innate ability to fight infection. ...
Breaking Medicine News(10 mins):Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Changes in processing, handling could reduce commercial fishing injuries 2Health News:Breaking bad mitochondria 2
... before marriage, say an overwhelming 91 percent in an SMS ... ,The survey, conducted by manoramaonline/yuva, saw 22,578 people ... was a must before marriage. Just 2,032 said that such ... just been published. ,According to the Kerala State ...
... and less inclined to follow a career in general practice, ... of Australia.// ,Dr Catherine Joyce, Senior Lecturer in ... and co-author of the study, says places in the general ... of the past six years. ,The study compared ...
... Org" is currently touring South Africa to raise awareness of ... ,Betty Chiu, a member of this organization has ... encouraging other youngsters to follow her example and get themselves ... Org' was established three years ago at a Canadian high ...
... links exist between Alzheimer's and Type 2 diabetes, which has ... forms of the same disease. ,Researchers have found ... is similar to the effect of Alzheimer's on the brain. ... International Conference on Alzheimer's Disease and Related Disorders in Madrid, ...
... investigators from the Howard Hughes Medical Institute, have developed ... unknown genetic mutations that can trigger cancerous growth. The ... analyse the proteins instead of the genes, which are ... reduced the time it takes to target the molecular ...
... clinic has been established by two leading fertility experts, ... ages of 45 with the// treatment. ,Professor ... leading authority in the field of IVF, and Paul ... to carry out pre-implantation genetic diagnosis that is the ...
Cached Medicine News:Health News:Majority of Keralites Vote in Favor of HIV Certificate Before Marriage 2Health News:Diabetes and Alzheimer's disease May be Two Sides of the Same Coin 2Health News:New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer 2Health News:New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer 3Health News:Scotland's First 'Stand-Alone' Private Fertility Centre Established 2Health News:Scotland's First 'Stand-Alone' Private Fertility Centre Established 3Health News:Scotland's First 'Stand-Alone' Private Fertility Centre Established 4
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Plate Reader is an eight channel photometer for the sequential and simultaneous reading of micro-plate strips with 96 wells. High technology, user friendly, powerful and reliable....
TC-98 elisa strip reader. Reads, calculates, and prints results for up to 12 wells in about 30 seconds. Single point calibration. Multi-point calibration....
Stat Fax 2200 Incubator shaker....
Medicine Products: